Harvard Bioscience prelim FY2023 revenue ~$112.3M; includes $5.1M discontinued product headwind

HARVARD BIOSCIENCE INC

2023-FY EPS reported -$0.08 revenue$112,250,000

Preliminary unaudited FY2023 revenue estimate of ~$112.3M, down from $113.3M in FY2022, with $5.1M net headwind from discontinued products.
Adjusted EBITDA for YTD Q3 2023 was $10.9M (13% of revenue), up 53% vs prior year; FY2022 adjusted EBITDA margin was 9.6%.
Company cites Covid portfolio optimization and supply chain challenges as revenue headwinds.
Guidance from Q3 2023 earnings (Nov 7, 2023) was for FY23 revenue down 11-14%; this presentation does not reaffirm guidance.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

HARVARD BIOSCIENCE INC reported full year 2023 results: revenue ~ $112.3M incl. $5.1M net discontinued*.

Period: full year 2023
Revenue: ~ $112.3M incl. $5.1M net discontinued*
Result: preliminary results

Exact text from the filing

Est. FY’23 Revenue: ~ $112.3M incl. $5.1M net discontinued*

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR

accession 0001171843-24-000099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.